Firmagon
What Firmagon is used for
FIRMAGON is a gonadotrophin releasing hormone (GnRH) antagonist indicated: - for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Firmagon
- Active substance
- degarelix
- Disease area
- Prostatic Neoplasms
- Medicine group
- Endocrine therapy
- ATC code
- L02BX02
- Marketing authorisation holder
- Ferring Pharmaceuticals A/S
- Authorised in the EU since
- 2009
Official information
In India
- Degarelix: 13 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Firmagon used for?
FIRMAGON is a gonadotrophin releasing hormone (GnRH) antagonist indicated: - for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
What is the active substance in Firmagon?
Firmagon contains degarelix.
Who makes Firmagon?
The EU marketing authorisation holder is Ferring Pharmaceuticals A/S.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU